O200 10-YEAR FOLLOW-UP OF A RANDOMISED CONTROLLED TRIAL COMPARING NEOADJUVANT CHEMORADIOTHERAPY PLUS SURGERY VERSUS SURGERY ALONE FOR OESOPHAGEAL OR JUNCTIONAL CANCER (CROSS)

Ben M. Eyck(Erasmus MC Cancer Institute), Maurice J.C. van der Sangen(Radboud University Nijmegen), Ernst Jan Spillenaar Bilgen(Radboud University Nijmegen), Geke A.P. Hospers(University Medical Center Groningen), Mark I. van Berge Henegouwen(University of Namur), Jannet C. Beukema(University Medical Center Groningen), Geert-Jan Creemers, Tom Rozema(Radboud University Nijmegen), Daan Nieboer(Erasmus MC), R.J.B. Blaisse(Rijnstate Hospital), Joël Shapiro(The Netherlands Cancer Institute), Hanneke W.M. van Laarhoven(Dutch Cancer Society), Grard A. P. Nieuwenhuijzen(Radboud University Nijmegen), Olivier R. Busch(Amsterdam Neuroscience), Cornelis J.A. Punt(Utrecht University), Herman van Dekken(Erasmus MC), Johannes J. Bonenkamp, Katharina Biermann(Rotterdam University of Applied Sciences), Miguel A. Cuesta(Hospital General Universitario de Albacete), Pieter van Hagen(Erasmus MC), Janny G. Reinders(Dutch Art Institute), J. Jan B. van Lanschot(Erasmus MC Cancer Institute), John Th. M. Plukker(University Medical Center Groningen), Maarten C.C.M. Hulshof(Academic Medical Center), Henk M.W. Verheul(Erasmus MC Cancer Institute), Anna H.M. Piet(Amsterdam University Medical Centers), Bas P. L. Wijnhoven(Inserm), Ate van der Gaast(Erasmus MC), Hugo W. Tilanus(Amsterdam UMC Location University of Amsterdam), Caroline M. van Rij(Erasmus MC), Berend J. van der Wilk(Erasmus MC Cancer Institute), Fiebo J.W. ten Kate
Diseases of the Esophagus
November 1, 2019
Cited by 0


Related Papers